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Abstract
Patient management in heart transplant is quite complex and includes multiple steps 
from preoperative recipient evaluation to postoperative ICU treatment. Monitoring, 
anesthesia induction, and cardiopulmonary bypass weaning strategies are discussed. 
The success of the operation also depends on right heart support especially in case of 
pulmonary hypertension. Many details like fluid management, well-timed respiratory 
weaning, and primary graft dysfunction management can make the difference in terms of 
outcome. Pediatric heart transplants represent a small group of total cardiac transplant, 
but the differences in anatomy and physiology make the surgical and anesthesiological 
management more complex in unique scenario that requires a specific knowledge at dif-
ferent stages of growth, from newborn through childhood up to adulthood.
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1. Intraoperative management
Intraoperative management in heart transplant is quite complex and includes multiple steps 
from preoperative evaluation to ICU admission.
1.1. Preoperative evaluation
During this phase, we need to collect the consent from the patient after having explained to 
him all the possible complications coming from surgery, anesthesia, and ICU stay.
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Above all, we need to know the background history of the patient, any previous issue with 
general anesthesia, allergies, difficult airway management, and any possible contraindication 
to the transplant itself [Table 1].
A multiorgan analysis must be taken into account:
• Neurological history: syncopal episodes, carotid stenosis, ischemic or hemorrhagic stroke, 
transitory ischemic attack.
• Respiratory history: smoke, COPD, spirometry, DLCO test.
• Cardiovascular history:
1. origin of cardiomyopathy: dilated/hypertrophic/ischemic cardiomyopathy
2. noncompaction left ventricle (LV), sarcoidosis, amyloidosis, and others
3. arrhythmias: episodes of sudden cardiac death syndrome, implantation of an ICD
4. right side catheterization: pulmonary artery pressures (PAP), pulmonary capillary 
wedge pressure (PCWP), pulmonary vascular resistances (PVR), results of reversibil-
ity test with enoximone, origin of pulmonary hypertension (prepost capillary)
5. presence of prosthetic valves in situ
6. home medications: oral anticoagulants, ace inhibitors, b-blockers, diuretics
• Renal history: chronic or acute renal failure, preoperative serum level of creatinine and 
urea, creatinine clearance, history of renal replacement therapy.
• Hepatobiliary history: a systemic portal venous congestion can often derive from chronic 
congestive heart failure. In this case, high levels of transaminases and bilirubin may occur 
and this may influence the pharmacological and hemodynamic management during 
anesthesia.
Absolute contraindications Relative contraindications
Significant COPD (FEV1 < 1 L/min) Age > 72 years
Fixed pulmonary hypertension Active infections
PAPs >60 mmHg BMI > 35 kg/m2 or <18 kg/m2
GTP > 15 mmHg Creatinine clearance < 25 ml/min
PVR > 6 wood units Active mental illness or psychosocial instability
Irreversible renal or hepatic dysfunction Severe peripheral vascular disease
AIDS/malignancy/lupus Diabetes mellitus with end organ damage
Table 1. Contraindications to heart transplantation.
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• Metabolic history: surgical stress and corticosteroid therapy may dramatically increase 
glycemia levels and hyperglycemia may dramatically increase the lactate levels during 
and after surgery; this is the reason why we need to know if the patient has diabetes and 
plan a proper blood glucose control with continuous infusion insulin (usually 50 UI/50 ml 
gelatin starting with a speed of 2–3 ml/h, depending on glucose plasma levels, with a target 
of 80–150 mg/dl). Among metabolic disorders, hypothyroidism can be further impaired 
during and after heart transplantation because plasma levels of triiodothyronine are often 
decreased during long periods of cardiopulmonary bypass, so that it’s important to plan an 
early replacement thyroid therapy.
• Preoperative fasting: the patient should fast from food at least 8 hours and from fluids 
4–6 hours before the operation.
• Premedication: it’s important to avoid any preoperative oversedation since hypoxia may 
increase the pulmonary vascular resistances (PVR). We usually do not exceed a dose of 
10—15 drops per os of diazepam in adult patients before going to theater, but, if the patient 
is really critical, we avoid any premedication.
1.2. Recipient with pulmonary hypertension
Severe pulmonary hypertension in the recipient is one of the major contraindications to heart 
transplant [1, 2] due to high risk of right heart failure. When pulmonary hypertension persists 
up to 1 year from transplant, clinical outcomes and percentage of long-term survival are really 
poor [3]. For the above-mentioned reasons, a potential recipient must be evaluated with cau-
tion before being added to the waiting list. First of all, he needs to be sent for cath lab in order 
to evaluate his own pulmonary vascular resistances (PVR), mean pulmonary arterial pressure 
(m-PAP), pulmonary artery wedge pressure (PAWP), cardiac output (CO), cardiac index (CI), 
and the transpulmonary gradient (TPG).
This last equals the difference between mPAP and wedge pressure (TPG = mPAP − PAWP).
In case of high PVR (PVR > 3 wood units [WU]), it is important to perform the reversibility 
test with enoximone or dobutamine in order to quantify the reversibility degree of pulmonary 
hypertension. When postcapillary pulmonary hypertension (defined as mPAP ≥ 25 mmHg, 
PAWP > 15 mmHg and PVR > 3WU) is unresponsive to dobutamine reversibility test 
(i.e., PVR > 3 WU or mPAP > 35 mmHg with a TPG > 12 mmHg), a team made of cardiologists, 
anesthesiologists, and cardiac surgeons should seriously evaluate if the patient is suitable for 
receiving a new heart.
A preventive treatment with pulmonary vasodilators such as sildenafil should be considered 
since it has been shown to decrease the PVR in a period of few months [4].
A preventive treatment with sildenafil should also be considered when patients are scheduled 
for receiving an LVAD positioning as bridge to transplant, thanks to its effectiveness in long-
term reduction of the PVR and major responsiveness to a further test with dobutamine [5].
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2. Monitoring and induction of general anesthesia
Timing to get the patient ready to receive the new organ is crucial because the ischemia of the 
donor heart should be as short as possible to avoid the ischemia-reperfusion injury.
Everyone in the theater should wear sterile surgical gown, hat, mask, and sterile gloves for 
any procedure on the patient especially because he will go under immune deficiency. Once 
the patient is in the theater, he will be connected to multiparametric monitor, with the 12 lead 
ECG and oximetry probe. Two peripheral venous lines are placed (generally 18G for iv seda-
tion and 14G for rapid fluid infusion), and an arterial catheter, generally 20G, is placed into 
the radial or humeral artery. When the patient is very unstable, an arterial catheter is placed in 
the left femoral artery, to estimate central to peripheral arterial pressure gradients. Placement 
of an arterial line can be very difficult in patients with previous implantation of LVADs as 
bridge to transplant, due to the absence of arterial pulse. In such situations, ultrasound guid-
ance can be very helpful (see Table 2).
Induction of general anesthesia usually starts just with the final acceptance of the donor organ. 
Drugs used for general anesthesia should impact the less possible on hemodynamics. A rapid 
sequence induction is preferred since recipients are always very stressed and sometimes not 
present with an empty stomach [6].
Midazolam (10–15 mg) or etomidate (20 mg) are preferred to propofol for hypnosis, due to the 
less impact on hemodynamics. Opioids like fentanyl or sufentanil are preferred for the same 
reason (“stress-free anesthesia”), with an induction dose of 0.2–0.4 mcg/kg for sufentanil and 
2–4 mcg/kg for fentanyl. Continuous infusion analgesia remifentanil is preferable for the less 
impact on renal function since it is metabolized by plasmatic esterase. This is particularly 
important in patients with low cardiac output and preexisting renal failure. Remifentanil will 
be turned off and replaced by morphine or tramadol (30 mg/die and 300 mg/die, respectively), 
before moving to the intensive care unit. Mean term muscle relaxant rocuronium (1 mg/kg) 
is usually the first choice for rapid sequence induction. Sometimes short-term cisatracurium 
Device Measure
PA radial Invasive arterial pressure (peripheral)
PA fem Invasive arterial pressure (central)
CVP Central venous pressure
ECG 12 lead electrocardiography
SpO2 Oxygen saturation levels
PAC (pulmonary artery catheter) PAPs, PAPm, PAPd, sVO
2
TEE Biventricular function, shape of ventricular septum, filling, air etc.
NIRS ScvO
2
 correlation, adequate tissue perfusion, brain perfusion
LAP LV filling pressure
Table 2. Standard monitoring.
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besylate (0.15–0.2 mg/kg for induction and 1–2 mcg/kg/min for continuous iv infusion during 
surgery) is a good alternative since it is metabolized by ester hydrolysis and Hofmann reac-
tion, so the duration of block is not affected by renal or hepatic function. During induction 
of general anesthesia, severe hypotension can occur, so that a fluid iv bolus ad availability 
of rapid onset vasoconstrictors as metaraminol, phenylephrine, noradrenaline should be 
ensured. Cardioplegia is not administered in the recipient during heart transplantation, so that 
the risk of related hemodilution is less than routine cardiac surgery. On pump, sevoflurane 
or iv 2% propofol infusion (4 mg/kg/h) are the options for maintenance of general anesthesia. 
Monitoring the depth of anesthesia with bispectral index (BIS) should be routinely adopted in 
order to decrease the risk of awareness. Once having put the patient asleep, central lines must 
be placed (queen central venous pressure [CVP] line and 8 Fr line for the pulmonary artery 
catheter [PAC]). The ideal site for puncture (blind or ultrasound-guided) is the left internal 
jugular vein (IJV), since the right one can be reserved for eventual postoperative biopsy (nec-
essary to evaluate the level of graft rejection). When this is not possible (presence of ICD on 
the left side), we can adopt the right subclavian vein. Sometimes, when the preoperative renal 
function is really compromised, we can already place into the femoral or subclavian vein a 
catheter for continuous renal filtration afterwards. The PA catheter is flown through the 8 Fr 
line up to the right atrium, and then, once the new heart is placed, it will be advanced by the 
cardiac surgeon up to the superior right pulmonary artery. Vigilance calibration will be done 
immediately before weaning from the CPB.
3. CPB and weaning
If the graft is not carried out into the organ care system (OCS), the ischemic time is crucial and 
the risk of ischemic/reperfusion injury is proportionally high, with possible dramatic increase 
of blood lactate levels and decrease of the graft global function. This is the reason why we 
must ensure adequate glycemia control, urine output, and, in general, an optimal tissue 
perfusion during CPB. This means to guarantee an adequate oxygen delivery (DO
2
), which 
means to keep MAPs about 60–80 mmHg and Hb levels at least about 8–9 mg/dL. When the 
aorta is unclamped, VF can occur (50% of patients). A shock delivery (10–30 J) followed by 
lidocaine bolus (when VF is refractory to electrical therapy) will take to resolution of the 
arrhythmia and return to sinus rhythm. In case of sinus bradycardia, temporary epicardial 
pacing will ensure adequate heart rate (100–110 bpm). Due to limited muscular mass, the 
ability of the right ventricle (RV) to increase contractility is limited and a temporary pacing at 
about 110 bpm will increase RV output and will overpace possible arrhythmias. Surgeons will 
also place a left atrial catheter for continuous measurement of the left atrial pressure (LAP) 
as an indicator of the left ventricle performance and stiffness. This value, together with CVP, 
PAPs, MAPs, and SvO2, will influence the posttransplantation hemodynamic management. 
Throughout this period, it will be mandatory to ensure adequate MAPs and diastolic pressure 
to allow adequate coronary perfusion, while maintaining medium-low preload pressures 
(CVP < 12 mmHg, LAP/PCWP < 12 mmHg). The biventricular assessment with transesopha-
geal echocardiography should be done simultaneously.
Pharmacological tools for CPB weaning will include the following [Tables 3 and 4]:
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• Isoprenaline at low-moderate dose (0.02–0.04 mcg/kg/min): it is the first choice in heart 
transplantation due to the positive chronotropic effect; it helps to guarantee a heart rate 
of 100–110 bpm. If it does not work, do not go beyond 0.04 mcg/kg/min, in order to avoid 
hypotensive effects. In this case, switching to atrial pacing is the best choice.
• Adrenaline (0.02–0.2 mcg/kg/min): it provides inotropic support to the new heart, espe-
cially to the right ventricle, which is the one more at risk of failure.
• Milrinone (0.2–0.5 mcg/kg/min) or other phosphodiesterase inhibitors (enoximone at 
5–8 mcg/kg/min): they increase contractility especially of the right ventricle, while decreas-
ing pulmonary vascular resistances. They both increase intracellular levels of cAMP, but 
they also decrease the systemic vascular resistances (SVR), so that the patient may benefit 
from low-moderate noradrenergic support in addition. If systemic peripheral resistances 
are really low, selective pulmonary vasodilators, aimed to decrease RV afterload without 
affecting peripheral resistances, are a better choice: inhaled nitric oxide (iNO) at 20–40 ppm 
[9, 17]) or aerosolized prostaglandins (iloprost 20 mcg/15 min, repeated after 4 hours).
Possible side effects of these selective inhalation drugs are inhibition of platelet activation 
and aggregation and inhibition of leucocyte adhesion.
• Levosimendan (0.1–0.2 mcg/kg/min) has also been reported to reverse low cardiac output 
after heart transplantation [10], although its use has not been shown to reduce cardiac 
surgery mortality [11].
After having unclamped the aorta and before weaning from CPB, about 1 hour of assistance to 
the new heart is provided. During this period, an adequate temperature is achieved (36–36.5°C 
measured by nasopharyngeal temperature probe). Vigilance calibration is performed by provid-
ing Hb levels and SvO
2
 from gas analysis; it gives results about the indexed cardiac output, 
pulmonary vascular resistances, and systemic peripheral vascular resistances, indexed on the 
patient weight. PAPs are shown on the monitor together with CVP, LAP, MAPs, and ECG. The 
PAVR (pulmonary artery vascular resistance) equals: PAVR = [80 × (mean pulmonary artery pres-
sure – pulmonary + capillary wedge pressure)/cardiac output] (normal value 100 dynes/cm−5).
The TPG (transpulmonary gradient) equals: TPG = mPAP − PCWP (normal value 6 mmHg).
A TPG > 15 mmHg is considered at high risk to develop early postoperative RV dysfunction 
[7]. The reason for RV dysfunction development may be found in the background of the donor 
heart. Especially when young and comparably small, it may not easily adapt to the already exist-
ing pulmonary hypertension in the recipient. Furthermore, as a result of a long ischemia and 
CPB time, with ischemia-reperfusion injury, RV dilates, becomes ischemic, and further reduces 
its own contractility. In this case, we need to adjust the amount of inotropes, chronotropes, 
and pulmonary vasodilators given, basing also on transesophageal echocardiography that can 
show the biventricular systolic-diastolic function and fluid responsiveness. Once the patient is 
stable and the heart rate is appropriate, we can start ventilation and slowly decrease the pump 
flow until 0.5–1 L/min. At that point, we come out from bypass. During CPB weaning, the heart 
should be loaded with caution because RV is very sensitive to distension. Echocardiographic 
parameters to asses the RV behavior will be RVFAC (fractional area change), leftward shift of 
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Drug Average dosage Advantages Side effects
Epinephrine 0.05–0.25 mcg/kg/min Support RV overload Tachycardia, arrhythmias, raise O
2
 
demand
Norepinephrine Up to 0.15 mcg/kg/min Contrast vasodilatation Increase PVR
Levosimendan 0.1–0.2 mcg/kg/min Support RV overload Vasodilation
Milrinone 0.2–0.5 mcg/kg/min Support RV overload Arrhythmias, raise O
2
 demand, 
vasodilation
Vasopressin 2.5–5 U/h Contrast vasodilatation Increase SVR impair forward flow 
of LVAD
i-NO 20–40 ppm Reduce PVR (if not fixed)
i-Milrinone 5 mg/15 min Reduce PVR (if not fixed)
i-Iloprost 20–30 mcg/15 min Reduce PVR (if not fixed)
Methylene blue 0.5–2 mg/kg Contrast vasodilation
Table 4. Inotropes/vasoactive: average therapeutic dosage to support hemodynamics.
Sustain SVR and arterial pressure (if necessary) Norepinephrine
vasopressin
Maintain DO
2
 level
272 ml/min/m2
Raise in pump flow
Raise Hb level
Raise O
2
 sat
Decrease body temp
Support graft Milrinone (0.2–0.5 mcg/kg/min)
Dopamine (4–6 mcg/kg/min)
Epinephrine (0.05–0.25 mcg/kg/min)
Hb level 11 g/dl
Maintain regular rhythm
and A-V synchrony
110 bpm
K+/Mg+
Pacing
Isoprenaline (0.02–0.04 mcg/kg/min)
Pacing with 110–120 bpm Increase of HR increases CI, avoid overload
Reduce PVR (if necessary) iNO (20–40 ppm)
Inhalatory iloprost (10–20 ng)
Inhalatory milrinone (5 mg) for 15 min
Slowly reduce CPB flow (careful monitoring CVP, TEE, LAP) Check/change drug infusion rate
Check chamber filling
Check contractility
Table 3. Practice guide to wean from CPB.
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IAS (interatrial septum) or “fluttering” of IVS (interventricular septum) during end-diastole, 
TAPSE(tricuspid annular plane systolic excursion), and MPI (myocardial performance index).
Basic ventilation strategies to reduce pulmonary artery resistances such as hyperoxia and 
moderate hyperventilation are mandatory. Ventilation should be set at 60–100% FiO
2
, 6–8 ml/
kg TV (tidal volume), and low-moderate PEEP (5–6 cmH
2
O), after recruitment maneuver, 
with the intention to prevent lung atelectasis [12].
Chest closure can be very critical for hemodynamics. In some rare cases (i.e., 2.5%), primary 
graft failure can occur [13], and it is responsible for more than 30% of early deaths after cardiac 
transplantation. Clinical onset of primary graft failure is with hypotension, low cardiac out-
put, high preload pressures (PVC, LAP, and wedge pressure), and biventricular failure. When 
necessary, a temporary IABP (intra-aortic balloon pump), as first step, and then peripheral 
(femoral vein-femoral artery) or central (left atrium, right atrium, aorta) VA-ECMO (venous-
arteriosus extracorporeal membrane oxygenation) should be taken into account, whenever 
hemodynamics remain unsatisfactory despite high inotropic support (Table 5) [14].
4. Fluid management
Fluid management should be “goal directed,” that is, guided by the above-mentioned hemo-
dynamic and echocardiographic parameters, and with the aim to avoid a fluid overload, 
which is very harmful for the lungs and the right ventricle, while providing adequate intra-
vascular space filling. This should be done via balanced colloids and crystalloids in order to 
avoid electrolyte disorders and hyperchloremic hyperkalemic metabolic acidosis. Adequate 
oxygen delivery is ensured by maintaining the hemoglobin level around 10–11 g/dL and an 
adequate plasma oncotic power is ensured by giving the right amount of albumin.
5. Anticoagulation and hemostasis
To go on CPB, we need to provide an appropriate anticoagulation via unfractionated hep-
arin (300–400 U/kg). A value of ACT at least of 480 s is enough to start the extracorporeal 
Inotropic score Dopamine (μg/kg/min) + dobutamine (μg/kg/min) + 100 × epinephrine 
(μg/kg/min)
Vasoactive inotropic score (modified by 
Davidson et al. with inclusion of vasoactive 
medication
IS + 10 × milrinone (μg/kg/min) + 10 × vasopressin (U/kg/
min) + 100 × norepinephrine (μg/kg/min
Vasoactive inotropic score plus 
levosimendan
VIS + 10 × levosimendan (mcg/kg/min)
Poor clinical outcome VIS 20–24 (in the first 24 h) + VIS 15–19 (in the subsequent 24 h)
Table 5. Inotropic score.
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circulation. In case of low response to a full dose of heparin, we can achieve an adequate ACT 
by administering antithrombin III (AT3), especially when AT3 plasma levels are less than 70%. 
From 0.5 to 5% of patients with end-stage heart disease can develop HIT (heparin-induced 
thrombocytopenia), due to repeated heparin exposures related to the placement of IABP, 
LVADs, or frequent catheter procedures. Alternative anticoagulation, with direct thrombin 
inhibitors (bivalirudin and argatroban), [8] is recommended in such patients. At the end of 
organ implantation, once the aortic and right atrium cannulas are removed, we need to guar-
antee an appropriate heparin reversal with protamine (50 mg of protamine every 50 mg of 
heparin). We also give the patient 2 g of tranexamic acid at the induction of general anesthesia 
and 2 g (25–50 mg/kg) with protamine in association with 1 g of gluconate calcium, to avoid 
hyperfibrinolysis and replace calcium deficiency. Severe bleeding is not a rare condition espe-
cially in patients with previous heart surgery. Particularly, in patients with LVADs as bridge to 
transplant, severe bleeding can often occur due to the large wound area and pretreatment with 
multiple anticoagulants and platelet inhibitors. If hemostasis is insufficient and the patient is 
still bleeding, we need to check for coagulation disorders via ROTEM (i.e., hyperfibrinolysis, 
coagulation factor deficiency, and hypofibrinogenemia) or via TEG and correct the specific 
deficiency (prothrombin complex concentrate for clotting factor deficiency or fibrinogen 
concentrate for hypofibrinogenemia). We prefer this approach instead of large dose of fresh 
frozen plasma, in order to avoid TACO (transfusion-associated circulatory overload), TRALI 
(transfusion-related lung injury), immune modulation, and increased risk of infections.
6. Intensive care management
Almost 90% of heart transplants are due to ischemic or dilatative cardiomyopathy and men 
over 40 years of age are the most involved. They all need a special care and a multimodal 
approach, even because not only cardiovascular balance but also respiratory care, fluid man-
agement, and immune system modulation impact on the overall survival.
6.1. ICU admission
Patients incoming from the operating room have to be placed in an isolated single bed room to 
avoid contamination, since they will undergo immunosuppressive therapy. Everyone in con-
tact with them must wear mask, cup, and sterile gown and do routine sterile hand washing. 
Invasive hemodynamic monitoring, including systemic arterial pressure, right atrial pressure, 
pulmonary artery pressure through the PAC, and left atrial pressure, should be immediately 
reconnected in the room.
Twelve lead ECG at the arrival is mandatory to check heart rhythm disorders. 
Bradyarrhythmias and supraventricular arrhythmias are the most frequent and should 
be related to inotropic and chronotropic support, hypovolemia, and electrolyte disorders. 
If atrial fibrillation occurs, an acute rejection should be considered and a 500 mg bolus of 
methylprednisolone should be administered, eventually followed by amiodarone (300 mg 
iv bolus in 30 min) for pharmacological cardioversion and rate control. In case of failure of 
pharmacological cardioversion, we can try electrical cardioversion. Sinus bradycardia can be 
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treated with low-dose isoprenaline (0.01–0.04 mcg/kg/min), adrenaline (0.01–0.04 mcg/kg/
min), and/or temporary atrial pacing, in order to ensure a heart rate about 100–110 bpm. In 
case of severe AV block, a sequential pacing is required. Anyway, if the patient is still pacing 
dependent after 2 weeks from the operation, implantation of a permanent pace maker should 
be considered. Then, you can proceed to request chest X-ray to check the lungs, endotracheal 
and nasogastric tube position, chest drains, and intravascular devices (CVP line, PAC, and 
pacing wires) and send for laboratory tests including standard coagulation, renal and liver 
function, platelets, red blood cell and white blood cell counts, troponin I, CK, albumin, viral 
markers, thyroid markers, and glycaemia. Blood samples should be sent for good practice 
also for coagulation tests (ROTEM or TEG) in case of excessive bleeding. A plan for immu-
nosuppressive therapy (methylprednisolone, thymoglobulins, etc.) must be provided in col-
laboration with specialist immunologist and cardiologist. Antibiotic therapy must be tailored 
on the background history of donor and/or recipient.
7. Hemodynamic management
Hemodynamic stability, after heart transplant, may be impaired by several pathophysiologi-
cal processes, including autonomic denervation, with subsequent chronotropic and inotropic 
failure, ischemia reperfusion injury, metabolic acidosis, and volume depletion. To support 
such effects, several endpoints must be taken into account:
7.1. Intravascular volume optimization
A goal-directed therapy is the ideal way to ensure adequate fluid filling. It means using the 
above-mentioned hemodynamic parameters coming from invasive monitoring and from 
echocardiographic evaluation, to be guided in the fluid replacement. Once the need of 
fluids is clear, the physician should decide the most ideal fluid in order to avoid periph-
eral organ oncotic damage (i.e., hyperoncotic kidney failure from hydroxyethyl starches 
[15]); hyperchloremic hyperkalemic acidosis, which can impact itself on kidney function; 
and fluid overload into the interstitial space. Crystalloids have a less oncotic power than 
colloids; however, albumin can cross the pulmonary capillary membrane, if damaged, 
and anyway it can recirculate through the pulmonary barrier 24 hours from the adminis-
tration: then balanced crystalloids and balanced colloids (albumin solution at 5 or 20%) 
should be given at the right per kilo amount and the fluid responsiveness should be tested 
while they are given.
7.2. Narrow monitoring of hemodynamic parameters
During the recovery period (approximately 7–14 days), a narrow monitoring of hemodynamic 
and vital parameters is mandatory: IBP, CI, CO, ISVRI, IPVR, PAPs, HR, SvO
2
, LAP/PCWP, 
TPG, SpO
2
, ECG, body temperature, urine output, and lactate levels.
Target values are: CVP ≤ 12 mmHg, MAP > 65 mmHg, LAP 8–12 mmHg, SvO
2
 over 65%, HR 
about 100–110 bpm, urine output > 1.5 ml/kg, and lactate < 2 mmol/L.
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7.3. Pharmacological support
The goal is to ensure adequate CO, avoiding excessive increase of cardiac preload and afterload, 
while maintaining adequate heart rate. Chronotropic support is achieved through low-moderate 
dose of isoprenaline or by atrial-sequential external pacing. Inotropic effect is achieved through 
moderate-high dose of adrenaline and, when necessary, with phosphodiesterase inhibitors as 
milrinone that also decreases peripheral vascular resistances. Other pharmacological tools that 
are aimed to control arterial ventricle coupling are nitroglycerin and sodium nitroprusside, 
very helpful to decrease the afterload of the left ventricle and increase cardiac output, when 
used together with an inotropic drug. In case of preexistent pulmonary hypertension, inha-
lation of nitric oxide and imbrication with sildenafil can help to reduce pulmonary vascular 
resistances [14]. In the further postoperative course, addition of an upstream therapy including 
ace inhibitors, b-blockers, or calcium antagonists may be helpful as cardiac protection.
7.4. Support the right ventricle of the donor heart
The donor heart, particularly the right ventricle, in case of preexisting precapillary or post-
capillary pulmonary hypertension, has to fight with high afterload [Table 6]. The preexist-
ing conditions may be impaired in case of coexisting hypoxia or hypercapnia, prolonged 
extracorporeal circulation, and donor ischemia with consequent ischemia-reperfusion injury, 
blood transfusion, and protamine administration. Right ventricular failure may be challeng-
ing and really impacts on the overall survival of transplanted patients [18].
Early PA pressure monitoring at the time of CPB weaning is fundamental and has to be con-
tinued in the early postoperative period. The first aim in hemodynamic management of the 
graft is to offload the right ventricle, decreasing PA pressures and pulmonary vascular resis-
tances while ensuring an adequate RV contractility. Inhaled nitric oxide at 20–40 ppm is a 
rapid onset tool to decrease PA pressures. It seems to improve early clinical outcomes in heart 
transplanted patients, but literature is still lacking in terms of overall survival [9].
This is the reason why it is often used preventively during weaning from the CPB. Alternatively, 
the prostacyclin analog iloprost (6 × 5–10 mcg) can be given.
After the very early postoperative period, inhaled nitric oxide can be substituted by the phos-
phodiesterase-5 inhibitor sildenafil at the dosage of 20 mg × 3/die via NG tube with very small 
effects on the systemic pressures, avoiding also the rebound phenomena coming from the 
discontinuation of inhaled nitric oxide therapy. Sildenafil has also been shown to decrease 
PA pressures during inhalation of nitric oxide, since they seem to activate different regulatory 
mechanisms of the vascular tone [19, 20]. Inotropic support of the RV should be guaranteed 
by moderate-high dose of adrenaline (0.05–0.1 mcg/kg/min) or low-moderate doses of phos-
phodiesterase inhibitors as milrinone (0.2–0.3 mcg/kg/min).
Clearly, while supporting the right ventricle, we need to ensure adequate oxygenation, avoid 
hypercapnia, maintain adequate lung recruitment by PEEP (not over 6 cmH
2
O), and guarantee 
a negative fluid balance in order to reduce the preload and optimize the afterload [Table 6]. 
If all these maneuvers are not sufficient, we have to consider a temporary mechanical right 
ventricle support via peripheral VA-ECMO.
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In case of concomitant LV insufficiency and signs of systemic hypoperfusion (with raising of 
LAP/PCWP and sudden reduction of CO, CI, and SvO
2
), we will need to increase the inotrope 
support and try to compensate the peripheral vasoconstriction with peripheral vasodilators 
as nitroprusside, when the MAPs allow to do that, in order to reduce left ventricle afterload 
and facilitate the ejection. The conditioning with inodilators as levosimendan [10] can be very 
helpful and, in case of massive peripheral vasodilatory response, it can be compensated with 
mean dosage of noradrenaline to ensure adequate MAPs. When this is not enough, an addi-
tional support with IABP should be considered, but, when insufficient, a central or peripheral 
VA-ECMO will be placed. The simultaneous presence of the IABP will help avoid pulmonary 
edema by reducing the afterload of LV.
7.5. Avoid metabolic acidosis and monitor acid-base balance and kidney function
A patient undergoing heart transplant comes from a long period of low cardiac output, so the 
kidney dysfunction is often preexisting.
In the immediate postoperative period, urinary output may decrease for several reasons 
including intravascular volume depletion and kidney damage coming from long lasting extra-
corporeal support or from the use of unbalanced solutions for fluid challenge. In addition, a 
high use of colloidal molecules may damage directly the renal tubules with a process called 
“osmotic-nephrosis.” If urine output is <0.5 ml/kg/h despite optimization of blood pressure, 
preload and CO, and use of standard diuretics (furosemide or torasemide), and the patient 
develops kidney failure with serum urea >200 mg/dL or hyperkalemia, kidney replacement 
therapy becomes mandatory.
We prefer early application of continuous venovenous hemofiltration (CVVH) for 
a complete hemodynamic and fluid rebalancing. In case kidney replacement therapy is 
Monitor by PAC CVP, MPAP, PCWP, CO, SvO
2
Mechanical ventilation PaO
2
 100 mmHg, pCO
2
 30–35 mmHg, pH 7.5. Adequate peep level (5–10 cm H
2
O) 
to recruit lung and optimize PVR
Restricted fluid therapy Monitoring filling pressure CVP 10–12 mmHg, PCWP 12–15 mmHg
Monitoring LVEDV, RVEDV by echocardiography
Inotropes to support RV 
contractility
Epinephrine 0.02–0.25 mcg/kg/min
Inodilator Milrinone 0.2–0.5 mcg/kg/min
Levosimendan 0.2 mcg/kg/min ± norepinephrine (up to 0.15 mcg/kg/min) to 
maintain right coronary perfusion pressure
iNO 5–40 ppm
Phosphodiesterase V inhibitor Revatio 3 × 20 mg p.o.
Systemic vasodilators Sodium nitroprusside, prostacyclin PGI
2
 analogon iloprost (2 ng/kg/min)
Table 6. Pulmonary artery hypertension monitoring and right ventricular dysfunction prevention.
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necessary in a long-term postoperative period, the change is made to intermittent dialysis 
(three times weekly).
7.6. Consider echocardiography as a main tool, together with PAC, to guide 
hemodynamic management, inotropic support, and fluid challenge
At first, we may exclude significant pericardial collection, assess left ventricle diastolic func-
tion of the new performing heart, related to its stiffness and hypertrophy, and think about 
which wedge pressure we are expected to find [21]. If the systolic function of the new heart 
is failing, we should exclude an acute graft rejection. Regarding the right ventricle, we must 
know the recipient preoperative pulmonary vascular resistances, if pre- or postcapillary pul-
monary hypertension persists and if it is reversible with phosphodiesterase inhibitors.
RV dysfunction is identified early with a dilation of the right chambers, alteration of interven-
tricular septum movement, and appearance of tricuspid valve insufficiency.
8. Respiratory weaning
A patient undergoing heart transplant should remain under mechanical ventilation until 
hemodynamic stability is ensured, lactate levels are stable, and immunosuppressive therapy 
is started. To protect the lungs, we have to limit peak pressures and use low tidal volumes 
(6 ml/kg) with adequate PEEP level (at least 3–5 cmH
2
O).
However, disadvantages coming from permissive hypercapnia on the pulmonary vascular 
resistances and right ventricle afterload, myocardial function, and renal blood flow loads 
must be taken into account [16]. As a consequence, there are no universal evidences, but the 
choice must be tailored for the patient. The only certainty is we must avoid hypercapnia, 
hypoxia, and PEEP over 10 cmH
2
O and keep peak pressure under 35–40 cmH
2
O.
During mechanical ventilation, inhaled nitric oxide can be administered in order to reduce 
right PA pressures, pulmonary vascular resistances, and then right ventricle afterload, espe-
cially in the first 24 hours from CPB weaning at the maximum dosage of 20–40 ppm [17, 18]. 
Once mechanical ventilation is discontinued, inhaled nitric oxide can be substituted by iv or 
oral pulmonary vasodilators as sildenafil. The weaning criteria do not differ from those used 
in normal cardiosurgical patients, and the goal is the same: maintain adequate analgesia and 
sedation levels and wean the patient from the mechanical ventilation as soon as possible. If 
this is not possible, due to unstable hemodynamics, high inotropic score, respiratory failure, 
or neurological issues, a percutaneous dilatation tracheostomy will be packaged without fur-
ther delay (within the first 5–7 days of mechanical ventilation).
Once the patient is awake and self-breathing and the LAP line is removed (generally 
24–48 hours from surgery), the patient will need physiotherapy and mobilization.
Early feeding is important. It is initially given via NG tube (25–30 kcal/kg/day) and then self-
feeding is achieved once there is no more gastrointestinal paresis.
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9. Infection control
Standard prophylaxis is due to cefuroxime 2 g iv every 6 hours in the first 24 hours from heart 
transplantation (the first two boluses are given in the operating room, at the induction of general 
anesthesia and once CPB is started). The amount of antibiotic given in the ICU should be tailored 
for the patient’s creatinine clearance, especially if the patient is not under renal filter. Further 
extension and change of antibiotic therapy should depend on microbiological results of the 
donor and on microbiological samples of the recipient once admitted in the ICU. Furthermore, 
in case of redo-operation with existing wound infection, the patient will receive vancomycin 
and meropenem as standard medication and vancomycin plasma levels should be tested daily. 
Obviously, due to the immunosuppressive therapy, transplanted patients are very prone to 
infections. Delivery of care should be done in sterile conditions and, besides standard iv antibi-
otic therapy, topical antifungal medications should be given in the early postoperative period.
10. Immunosuppressive therapy
A specific team is taking care of immunosuppressive therapy. It starts with 500 mg iv bolus 
of solumedrol at the CPB weaning. Once admitted in the ICU, the patient will receive 125 mg 
bolus of solumedrol every 8 hours, with a specific descending dose scheme.
Antithymocyte globulines (1.5 mg/kg iv) are usually given 4, 24, and 48 hours after the end 
of the transplantation. They will be adjusted based on eventual presence of high body tem-
perature, bleeding, and thrombocytopenia. There are several possible immunosuppressive 
agents that will be tailored for the patient such as tacrolimus, cyclosporin A, everolimus, and 
mycophenolate.
11. Graft dysfunction
An international consensus conference in 2014 has classified the graft dysfunction into pri-
mary graft dysfunction (PDG) and secondary graft dysfunction (SGD). The first one occurs 
24 h from heart transplant and can involve the left, the right ventricle, or both, with different 
degrees of dysfunction. Typical signs are severe deficit of systolic function, low cardiac out-
put, and high filling pressures without evidence of acute graft rejection or cardiac tamponade. 
The SGD has a specific reason such as acute rejection, pulmonary hypertension, or surgical 
complications. Risk factors to develop PGD may be related to the recipient, donor, or techni-
cal factors [22].
Donor-related risk factors may be:
• Age (increased risk of 20% every decade)
• Sex (nearly doubled risk with female)
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Recipient-related risk factors may be:
• High vasoactive or inotropic support (doubled risk)
• Uncontrolled diabetes (doubled risk)
Technical risk factors are:
• Warm ischemic time (= explant time + implant time); implant time was found to be a strong 
predictor of PGD.
• Resternotomy (it has been identified as a risk factor for severe PGD due to adherences and 
tissue fibrosis that can extend the explant time and increase the risk of infections).
• Prolonged CPB time, with subsequent systemic inflammatory response, vasoplegia, clot-
ting and platelet dysfunction, leukocyte activation, free oxygen radical release, and larger 
amount of blood products given.
All these factors can increase the ischemic-reperfusion injury and the overall mortality [23].
The first step to treat a PDG is vasoactive and inotropic support. If it were not sufficient, an 
intra-aortic balloon pump (IABP) placement may help.
In case of very severe PGD, an extracorporeal membrane oxygenation (ECMO) becomes the 
only emergency treatment.
11.1. Anesthesia and intensive care management
11.1.1. For cardiac transplantation in pediatrics
Pediatric heart transplant represents a small subgroup (14%) of total cardiac transplant where 
the differences in anatomy and physiology make the surgical procedure and the management 
more complex and creates a unique scenario [24].
The management of pediatric patients undergoing cardiac transplantation differs from the 
adult patients because it requires a specific knowledge of physiology and physiopathology at 
different stages of growth, from the newborns through childhood up to adulthood.
This heterogeneous population with a wide range of age, genetic disorders, anatomical 
anomalies, and symptoms can be classified in four different groups based on the different 
etiology: 1—CHD (congenital heart disease); 2—DCM (dilated cardiomyopathy); 3—RETX 
(retransplant); 4—OTHER (Table 7) [25]; each of these has specific features.
11.1.2. Preoperative evaluation
The preoperative evaluation is an essential step in order to better analyze both the cardiac 
pathology and the possible related comorbidities.
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Main preoperative features and examinations that must be considered are:
• Type of heart disease (CHD, DCM, RETX, and OTHER)
• Right heart catheterization (RHC): pulmonary artery pressure (PAP), pulmonary capillary 
wedge pressure (PCWP), pulmonary vascular resistances (PVR), and pulmonary hypertension 
etiology. Unfortunately, most patients with congenital heart defects have high PVR because of 
pulmonary vascular disease. However, the presence of systemic-to-pulmonary shunts, intra-
pulmonary shunting, and caval pulmonary circulation does not allow a correct assessment 
of PVR. For these patients, RHC should be performed at 3–6 month interval in adult patients 
but is not advocated as routine surveillance in children unless a clinical change is noted [26].
• Numbers and types of previous operations (sternotomy and thoracotomy).
• Cyanotic congenital heart disease (secondary erythrocytosis, hyperviscosity, and coagula-
tion deficit).
• Panel reactive antibody (PRA) identifies sensitized patients. It may be elevated in patients 
with allograft patch or with multiple redo-operations, due to the multiple transfusions. It 
may result in an increased risk of acute rejection [27].
• Variable anatomic substrates (isomerism, issues of situs, MAPCAs, aberrant right or left 
subclavian artery, and persistence of left superior vena cava).
• Previous venous or arterial thromboembolism (central venous catheter thrombosis).
• Previous neurological history: syncope, previous stroke, and cerebral arteriovenous 
malformation.
• Respiratory insufficiency: smoke, chronic obstructive pulmonary disease (COPD), anatom-
ical anomalies of the pulmonary vessels, and presence of bronchial or pulmonary stents.
• Arrhythmias and previous ICD implantation.
• Liver disease: an evaluation of the patient’s liver profile is extremely important. Chronic 
heart failure and in particular the univentricular heart physiology can lead to a liver 
dysfunction.
Category (abbreviation) Diagnoses in category
Congenital heart disease 
(CHD)
Congenital heart defects: HLHS-unoperated, with surgery, without surgery, 
valvular heart disease
Dilated cardiomyopathy 
(DCM)
Dilated myopathy due to alcohol, familiar, idiopathic, myocarditis, viral, 
postpartum, etc.
Retransplant (RETX) Due to acute rejection, coronary artery disease, etc.
Other (OTHER) Arrhythmogenic right ventricular dysplasia, cancer, coronary artery disease, 
myopathy-ischemia, hypertrophic cardiomyopathy, etc.
Table 7. Diagnosis for pediatric heart transplant.
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Fontan-associated liver disease (FALD) is a liver dysfunction due to a chronic elevated cen-
tral venous pressure, low cardiac output, persistent hypoxemia, and intrahepatic venous 
thrombosis. FALD can be expressed in different stages, from moderate hepatic congestion up 
to liver cirrhosis with portal hypertension. In several cases, liver function is preserved or is 
only slightly altered, with high international normalizer ratio (INR), low factor V levels, and 
elevated factor VIII levels [28].
• Kidney disease: acute or acute-on-chronic renal dysfunction.
• Coagulation anomalies may be present as result of chronic anticoagulation, liver disease, 
or as a result of cyanotic congenital heart disease (reduced levels of coagulation factors II, 
V, VII, IX, and X, accelerated fibrinolysis, and fibrinogen alterations).
• Gastrointestinal disorders: necrotizing enterocolitis in newborns or protein losing enter-
opathy (PLE), which is an excessive protein loss through the gastrointestinal tract that can 
be present after Fontan operation (even if its origins are poorly understood) [29]
12. Intraoperative management
The anesthetic management should consider that these patients have a poor cardiac reserve 
and that the premedication, general anesthesia, and the surgical manipulation after the ster-
notomy can lead to a destabilization of the hemodynamics.
Antibiotic therapy differs according to age and weight and background of both the donor and 
recipient (Tables 8 and 9).
Immunosuppression is started 1 hour before going to the operating room: thymoglobulin 
1 mg/kg/12 h and methylprednisolone 7–10 mg/kg (max. 125 mg).
Premedication is performed, according to clinical condition, with low doses of benzodiaz-
epines (midazolam 0.3–0.5 mg/kg orally or rectal in neonate) avoiding excessive sedation and 
consequently hypercapnia.
It is well known that in newborns and infants, placing an invasive monitoring before induc-
tion of anesthesia is not always possible; therefore, it is essential to have a noninvasive moni-
toring before starting the drug administration.
General anesthesia is induced by inhalation of sevoflurane/desflurane in newborns and infants 
and by intravenous injections of midazolam 0.3–0.5 mg/kg, fentanyl 2–4 mcg/kg, rocuronium 
1 mg/kg, and propofol 2–4 mg/kg in adults and children. Moreover, for continuous infusion 
of the anesthesia, propofol 4–6 mg/kg/h in adults, while midazolam 0.2 mg/kg/h and fentanyl 
2 mcg/kg/h in newborns and children are recommended. After induction, hydrocortisone 
10–20 mg/kg is infused.
In all patients, regional cerebral monitoring is achieved with the use of near infrared spectros-
copy (NIRS).
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Different conditions may complicate the venous central catheter placing as: anatomical vari-
ables, possible occlusion due to previous repeated catheterizations, and previous positioning 
of central lines. In these cases, the echo-guided assistance is recommended. In smaller patients 
or in occluded jugular/subclavian veins, femoral veins can be also used. The sizing of the 
catheter and the numbers of lumens used depend on the weight and age of the patients. When 
possible, a pulmonary artery catheter (PAC) must be placed into the superior vena cava and 
then correctly repositioned by the cardiac surgeon before removing the aortic cross-clamp. In 
newborns and infants, placing PAC may be problematic or impossible due to the size of the 
patient. In these cases, it is possible to use the central venous oxygen saturation (SCvO
2
) as a 
surrogate of SVO
2
 even if the results are controversial [30].
As an alternative, the left atrial pressure (LAP) can be monitored with the insertion of a cath-
eter through the right superior pulmonary vein.
Transesophageal echocardiography (TEE) is always recommended for a correct evaluation of 
biventricular function, after the CPB weaning, accordingly with the patient’s weight.
After induction of the anesthesia, the ventilation management requires extreme attention 
since the hypoxia and the hypercapnia can increase PVR leading to a low cardiac output 
syndrome. In case of hypotension, before infusing, a bolus of colloid is essential to secure the 
correct ventilation, avoiding respiratory acidosis.
The majority of patients with CHD undergoing cardiac transplantation are reoperation can-
didates, so it is important to put into account long operative times, due to dissection of the 
adhesions and complex reconstruction of the anatomy.
Newborn < 1200 g 5 mg q 12 h
Newborn = 2000 g < 7 days of life 5 mg q 12 h
Newborn = 2000 g > 7 days of life 5 mg q 8 h
Newborn > 2000 g < 7 days of life 5 mg q 8 h
Newborn > 2000 g > 7 days of life 5 mg q 6 h
Infants and children 15/40 mg/kg/24 h in 3–4 doses
In case of allergy to beta-lactams, clindamycin is administered.
Table 9. Antibiotic therapy (clindamycin).
Newborn < 1200 g 20 mg q 12 h
Newborn ≥ 1200 g < 7 days of life 20 mg q 12 h
Newborn ≥ 1200 gr > 7 days of life 20 mg q 8 h
Infants and children 100 mg/kg/24 h in 3 doses
Table 8. Antibiotic therapy (cefazolin).
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12.1. CPB and weaning
CPB management can be extremely complex and differs according to the patient’s weight 
and age. The main aim is to maintain a correct medium arterial pressure (MAP) and a correct 
DO
2
/VO
2
 ratio.
Sometimes, this is difficult to be achieved, due to the possible presence of anatomical extra-
cardiac shunts. The dose of unfractionated heparin for the CPB is 200 U/kg in newborns 
and infants or 300 U/kg in the child and adult, in order to have an ACT > 400 s. In case of 
reduced response to heparin, administration of ATIII at a dose of 100 mg/kg is recommended. 
Furthermore, in case of HIT or low response to heparin, direct thrombin inhibitors are 
administered (bivalirudin and argatroban) as in adult patients. After the aortic cross-clamp is 
removed, methylprednisolone is administered with the dose of 7–10 mg/kg (max. 125 mg/kg).
Weaning from CPB always requires inotropic support and the right ventricular failure is a 
possible complication, characterized by restrictive pattern that can be managed by inhaled 
nitric oxide (5–40 ppm) and inotropic support (milrinone 0.3–0.75 mcg/kg/min, adrenaline 
0.02–0.1 mcg/kg/min, and isoprenaline 0.1–1 mcg/kg/min) in order to vasodilate the pulmo-
nary circulation improving biventricular contractility and providing a chronotropic effect if 
bradycardia occurs. It is extremely important to keep normal PVR by providing a proper 
ventilation, avoiding hypoxia and maintaining normocapnia.
Once the patient has been weaned form CBP, the vigilance or SCvO
2
 can monitor the hemody-
namic profile and biventricular function can be evaluated with echocardiogram.
However, in case of poor CO, despite maximal inotropic support and correct ventilation, we 
should consider the support via an extracorporeal membrane oxygenation (ECMO).
12.2. Anticoagulation and hemostasis
At the end of CPB, heparin is antagonized with a ratio 2:1 or 1:1 with protamine based on the 
ACT values. Antifibrinolytic agents are administrated at the dosage of 50 mg/kg (25 mg/kg after 
general anesthesia induction and 25 mg/kg at the end of CPB). Severe bleeding is not uncommon 
in pediatric population. Main reasons of postoperative bleeding are previous heart surgery, 
cyanotic congenital heart disease, immature coagulation system, and excessive hemodilution 
due to the disproportionate ratio of CPB circuit volume to patient blood volume, especially in 
newborns and infants. Correct coagulation management is always achieved through ROTEM.
12.3. Intensive care
During the postoperative intensive care course, close monitoring of hemodynamic param-
eters, inotropes, ventilation, and acid base balance is required to predict pulmonary hyper-
tension, biventricular failure, and LCOS. Normalization of the oxygenation and ventilation 
is the primary goal in these patients and ventilation support must be discontinued as soon 
as possible. The antibiotic therapy will be set according to microbiological surveillance. 
Immunotherapy during the postoperative course is managed by the cardiologist as follows: 
methylprednisolone, thymoglobulin, tacrolimus, and mycophenolate.
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12.4. Peculiar problems
In the postoperative setting, the main problems for pediatric patients are comorbidities related 
to chronic decompensation and univentricular physiology.
• Cyanotic congenital heart disease: patients with long standing hypoxemia often develop 
severe alteration of whole blood viscosity and alteration of coagulation profiles with high 
risk of postoperative bleeding [31].
• Plastic bronchitis: it is a rare complication of univentricular physiology characterized by 
the formation of exudative airway casts that can occlude airways and cause respiratory 
failure. The etiology is still not well identified, but it seems to relate to an increased central 
venous pressure or lymphatic drainage alterations [32].
• Protein losing enteropathy (PLE): it is defined as a possible complication of the univen-
tricular circulation. It can arise after the Fontan operation (5–15% of the patients) [33]. It 
is characterized by the abnormal loss of proteins into the enteral lumen, which results in 
hypoproteinemia and hypoalbuminemia. This leads to an increase of lymphatic drainage 
and a dilation of intestinal lymphatic system with an impaired fat absorption resulting in 
steatorrhea. Moreover, the hypoproteinemia may result also in ascites, peripheral edema, 
and pleural/pericardial effusion. Therapy consists of diuretics, corticosteroids, and albu-
min supplementation.
Abbreviations
BIS bispectral index
CI cardiac index
CO cardiac output
COPD chronic obstructive pulmonary disease
CPB cardiopulmonary bypass
CVC central venous catheter
CVP central venous pressure
CVVH central venovenous hemofiltration
DLCO carbon monoxide lung diffusion
ECMO extracorporeal membranous oxygenation
HIT heparin-induced thrombocytopenia
IABP intra-aortic balloon pump
ICD implantable cardioverter defibrillator
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ISVR indexed systemic vascular resistance
LAP left atrial pressure
LV left ventricle
LVAD left ventricular assist device
NGT nasogastric tube
NO nitrogen oxide
OCS organ care system
PAC pulmonary artery catheter
PAP pulmonary arterial pressure
PCWP pulmonary capillary wedge pressure
PEEP positive end expiratory pressure
PPM parts per millions
PGD primary graft dysfunction
PVR pulmonary vascular resistance
RAP right atrial pressure
RV right ventricle
SIRS systemic inflammatory response syndrome
SVR systemic vascular resistance
TACO transfusion-associated circulatory overload
TPG transpulmonary pressure gradient
TRALI transfusion-associated lung injury
TV tidal volume
VAD ventricular assist device
WU wood unit
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